Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Mikhail V. Blagosklonny subsequently
Relocated to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ lab at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Different biomedical topics, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author for a clinical phase I/II
Trial publication.
 
After authoring seven papers during a brief yet fruitful
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published a
Lot of experimental research papers and theoretical papers as lead
Author. These sole-author articles
Included two important themes.
The first of those discussed selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Confirming their resistance. The results and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the article was
Named, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint paper in 2001.
 
The second topic throughout Dr. Blagosklonny’s sole-author works
Is a research methodology to create knowledge by
Uniting several facts together from seemingly unrelated fields.
This results in new notions with testable predictions, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 publication in Nature. The
First success of the new research methodology was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Crucial result discovered by Dr.
Blagosklonny’s research methodology is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others don' t even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He went on to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since coming to Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Stopping body aging — in other words, “preventing cancer
By remainng young. ” His laboratory closely worked together with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging
Medicines beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models such as
Standard and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the stoppage of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer prevention in mice, and combinations of anti-
Aging medicines to be used in humans. A
Rapamycin-based combination of seven clinically available medications has
Been named the “Koschei Formula” and is now used for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://www.crunchbase.com/person/mikhail-blagosklonny#section-overview
https://www.tandfonline.com/doi/pdf/10.4161/cbt.8.9.8899
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482593/